Canagliflozin OK'd for Preventing HF Hospitalization in T2D
Expanded indications for patients with diabetic kidney disease
WASHINGTON -- In another label expansion, the FDA approved new cardiovascular and renal prevention indications for canagliflozin (Invokana), according to a statement from the Janssen unit of Johnson & Johnson.